Menu Search
Equities

Genelux Corp

GNLX:NAQ

Genelux Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.37
  • Today's Change-0.08 / -3.27%
  • Shares traded54.46k
  • 1 Year change-91.36%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy0
Outperform5
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 5 analysts offering 12 month price targets for Genelux Corp have a median target of 19.00, with a high estimate of 32.00 and a low estimate of 10.00. The median estimate represents a 701.69% increase from the last price of 2.37.
High1,250.2%32.00
Med701.7%19.00
Low321.9%10.00

Earnings history & estimates in USD

On Aug 14, 2024, Genelux Corp reported 2nd quarter 2024 losses of -0.22 per share.
The next earnings announcement is expected on Nov 15, 2024.
Average growth rate-0.95%
Genelux Corp reported annual 2023 losses of -1.16 per share on Mar 29, 2024.
Average growth rate-103.51%
More ▼

Revenue history & estimates in USD

Genelux Corp did not report revenues for the 2nd quarter 2024. However, during the 2nd quarter of the prior year the company reported revenues of 170.00k.
Average growth rate-33.33%
Genelux Corp had revenues for the full year 2023 of 170.00k. This was 98.46% below the prior year's results.
Average growth rate-98.46%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.